<DOC>
	<DOCNO>NCT02805829</DOCNO>
	<brief_summary>This trial evaluate safety effectiveness activate expanded vitro autologous NK cell follow trastuzumab treatment patient Human Epidermal Receptor-2 overexpressing advanced gastric cancer .</brief_summary>
	<brief_title>Combination Trastuzumab With Expanded Natural Killer Cells Treating HER2-positive Gastric Cancer</brief_title>
	<detailed_description>Tumor antigen-specific monoclonal antibody , block oncogenic signal induce Fcγ receptor ( FcγR ) -mediated cytotoxicity , consider one successful strategy cancer therapy . Trastuzumab , monoclonal antibody direct HER2 , investigated combination chemotherapy first-line treatment HER2-positive advance gastric cancer . The use cellular immunotherapy increase significantly past two decade . Natural killer cell lymphocytes innate immune system ability recognize kill malignant cell . There grow evidence show antibody-dependent cell-mediated cytotoxicity ( ADCC ) NK cell contribute efficacy Herceptin . Therefore , method enhance ADCC , stimulate innate immune response , may clinically translate improved antitumor activity . In study , investigator seek enhance clinical activity trastuzumab , administrate combination expand autologous NK cell . The enrolled patient diagnose HER2+ advance gastric cancer . The eligible patient administrate herceptin 2 day prior blood collection . The initial dose herceptin 8 mg/kg 90 minute IV infusion . On day 0 peripheral blood mononuclear cell separate 40-50ml blood density gradient centrifugation . Then culture human NK cell culture medium stimulation cytokine humidify , 5 % carbon dioxide incubator 14 day . After NK expansion verification result NK cell meet purity , gram stain , endotoxin release criterion , NK cell wash resuspend isotonic sodium chloride . NK cellular therapy conduct 2 cycle per year . The maintenance dose herceptin monotherapy 6 mg/kg 30 90 minute IV infusion every 3 week . This study determine safety efficacy novel combinational therapeutic strategy HER2 positive gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age equal 18 year old ; Patients histologically confirm HER2 positive advance gastric cancer immunohistochemistry ( IHC ) fluorescence situ hybridization ( FISH ) ; Normal marrow hematopoiesis function : Hemoglobin≥90g/L , White Blood Cell count≥4000/μL , absolute Neutrophil Cell count ( ANC ) ≥1500/μL , Platelet≥100000/μL ; Normal important organ function : Total bilirubin≤1.5fold institutional upper limit normal ( ULN ) , Aspartate aminotransferase Alanine aminotransferase≤2.5fold ULN , Creatinine clearance≥80mL/min ; Life expectancy≥6 month ; No serious heart , lung , kidney dysfunction ; Quality life ( Karnofsky performance score ) ≥60 ; Patient must able understand willing sign write informed consent document . Prior allergic reaction hypersensitivity cytokine ( eg.Interleukin2 ) ; Patients systemic local infection require antiinfections treatment ; Patients currently treat systemic immunosuppressive agent , include steroid ; Patients active autoimmune disease history transplantation require steroid treatment ; Tested positive HIV ; Pregnant lactate woman ; Patients coagulation disorder ; Patients important organ dysfunction , include cardiac , lung , liver ; Patients experience cardiac event ( acute coronary syndrome , myocardial infarction ischemia ) within 3 month ; Any reason , opinion investigator , contraindicate patient participates study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>NK cell</keyword>
	<keyword>Trastuzumab</keyword>
</DOC>